You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClarithromycin
Accession NumberDB01211  (APRD00181)
TypeSmall Molecule
GroupsApproved
DescriptionClarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Structure
Thumb
Synonyms
6-O-methyl erythromycin
6-O-Methylerythromycin
6-O-Methylerythromycin a
CLA
CLARITHROMYCIN
Clarithromycina
Clarithromycine
Clarithromycinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-clarithromycingranules for suspension125 mgoralAccel Pharma Inc2012-09-04Not applicableCanada
Accel-clarithromycingranules for suspension250 mgoralAccel Pharma Inc2012-09-04Not applicableCanada
Act Clarithromycin XLtablet (extended-release)500 mgoralActavis Pharma Company2014-12-01Not applicableCanada
Ava-clarithromycintablet250 mgoralAvanstra Inc2011-09-192014-08-21Canada
Ava-clarithromycintablet500 mgoralAvanstra Inc2011-09-192014-08-21Canada
Biaxintablet, film coated250 mg/1oralREMEDYREPACK INC.2013-03-13Not applicableUs
Biaxintablet, film coated500 mg/1oralAbb Vie Inc.1991-10-31Not applicableUs
Biaxintablet, film coated, extended release500 mg/1oralPhysicians Total Care, Inc.2000-11-03Not applicableUs
Biaxintablet, film coated250 mg/1oralAbb Vie Inc.1991-10-31Not applicableUs
Biaxingranules for suspension250 mgoralBgp Pharma Ulc2002-05-28Not applicableCanada
Biaxintablet, film coated500 mg/1oralA S Medication Solutions Llc1991-10-31Not applicableUs
Biaxingranules for suspension125 mgoralBgp Pharma Ulc1995-12-31Not applicableCanada
Biaxingranule, for suspension125 mg/5mLoralAbb Vie Inc.1993-12-23Not applicableUs
Biaxintablet, film coated500 mg/1oralCardinal Health1991-10-31Not applicableUs
Biaxintablet, film coated, extended release500 mg/1oralA S Medication Solutions Llc2000-03-03Not applicableUs
Biaxintablet, film coated, extended release500 mg/1oralAbb Vie Inc.2000-03-03Not applicableUs
Biaxintablet, film coated500 mg/1oralREMEDYREPACK INC.2013-02-25Not applicableUs
Biaxingranule, for suspension250 mg/5mLoralPhysicians Total Care, Inc.2007-05-01Not applicableUs
Biaxingranule, for suspension250 mg/5mLoralAbb Vie Inc.1993-12-23Not applicableUs
Biaxin Bidtablet500 mgoralBgp Pharma Ulc1994-12-31Not applicableCanada
Biaxin Bidtablet250 mgoralBgp Pharma Ulc1992-12-31Not applicableCanada
Biaxin XLtablet (extended-release)500 mgoralBgp Pharma Ulc2002-05-22Not applicableCanada
Clarithromycingranules for suspension250 mgoralSanis Health Inc2013-09-05Not applicableCanada
Clarithromycintablet500 mgoralSivem Pharmaceuticals Ulc2015-07-22Not applicableCanada
Clarithromycinfor suspension125 mg/5mLoralZydus Pharmaceuticals USA Inc1991-10-31Not applicableUs
Clarithromycinfor suspension250 mg/5mLoralZydus Pharmaceuticals USA Inc1991-10-31Not applicableUs
Clarithromycintablet250 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Clarithromycintablet250 mgoralPro Doc Limitee2009-10-08Not applicableCanada
Clarithromycintablet500 mg/1oralKAISER FOUNDATION HOSPITALS2009-10-01Not applicableUs
Clarithromycintablet500 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Clarithromycintablet, film coated250 mg/1oralZydus Pharmaceuticals USA Inc1991-10-31Not applicableUs
Clarithromycintablet500 mgoralPro Doc Limitee2009-10-08Not applicableCanada
Clarithromycingranules for suspension125 mgoralSanis Health Inc2013-09-05Not applicableCanada
Clarithromycintablet250 mgoralSivem Pharmaceuticals Ulc2015-07-22Not applicableCanada
Clarithromycintablet, film coated500 mg/1oralZydus Pharmaceuticals USA Inc1991-10-31Not applicableUs
Dom-clarithromycintablet500 mgoralDominion Pharmacal2010-10-01Not applicableCanada
Mylan-clarithromycintablet250 mgoralMylan Pharmaceuticals Ulc2007-07-26Not applicableCanada
Mylan-clarithromycintablet500 mgoralMylan Pharmaceuticals Ulc2007-07-26Not applicableCanada
PMS-clarithromycintablet250 mgoralPharmascience Inc2007-08-10Not applicableCanada
PMS-clarithromycintablet500 mgoralPharmascience Inc2007-08-10Not applicableCanada
Ran-clarithromycingranules for suspension125 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-clarithromycintablet250 mgoralRanbaxy Pharmaceuticals Canada Inc.2011-02-01Not applicableCanada
Ran-clarithromycintablet500 mgoralRanbaxy Pharmaceuticals Canada Inc.2011-02-01Not applicableCanada
Ran-clarithromycingranules for suspension250 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-clarithromycin XLtablet (extended-release)500 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ratio-clarithromycintablet250 mgoralRatiopharm Inc Division Of Teva Canada Limited2007-07-262014-09-19Canada
Ratio-clarithromycintablet500 mgoralRatiopharm Inc Division Of Teva Canada Limited2007-07-262014-09-19Canada
Riva-clarithromycintablet250 mgoralLaboratoire Riva Inc2010-06-162013-07-31Canada
Riva-clarithromycintablet500 mgoralLaboratoire Riva Inc2010-06-16Not applicableCanada
Sandoz Clarithromycintablet500 mgoralSandoz Canada Incorporated2008-06-06Not applicableCanada
Sandoz Clarithromycintablet250 mgoralSandoz Canada Incorporated2008-06-06Not applicableCanada
Sandoz Clarithromycin XLtablet (extended-release)500 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Teva-clarithromycintablet500 mgoralTeva Canada Limited2012-05-09Not applicableCanada
Teva-clarithromycintablet250 mgoralTeva Canada Limited2012-05-09Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-clarithromycintablet500 mgoralApotex Inc2007-07-26Not applicableCanada
Apo-clarithromycintablet250 mgoralApotex Inc2007-07-26Not applicableCanada
Apo-clarithromycin XLtablet (extended-release)500 mgoralApotex Inc2014-09-03Not applicableCanada
Clarithromycintablet, film coated500 mg/1oralPd Rx Pharmaceuticals, Inc.2006-05-31Not applicableUs
Clarithromycintablet, film coated250 mg/1oralAurobindo Pharma Limited2012-07-25Not applicableUs
Clarithromycintablet500 mg/1oralAvera Mc Kennan Hospital2015-03-02Not applicableUs
Clarithromycintablet, film coated500 mg/1oralKAISER FOUNDATION HOSPITALS2010-10-27Not applicableUs
Clarithromycintablet500 mg/1oralPd Rx Pharmaceuticals, Inc.2005-08-25Not applicableUs
Clarithromycintablet, coated500 mg/1oralBlenheim Pharmacal, Inc.2015-12-02Not applicableUs
Clarithromycintablet500 mg/1oralREMEDYREPACK INC.2011-07-08Not applicableUs
Clarithromycingranule, for suspension125 mg/5mLoralRanbaxy Pharmaceuticals Inc.2007-10-03Not applicableUs
Clarithromycintablet, film coated500 mg/1oralAmerican Health Packaging2013-06-202015-11-30Us
Clarithromycintablet, coated250 mg/1oralRoxane Laboratories, Inc2004-11-22Not applicableUs
Clarithromycintablet250 mg/1oralSandoz Inc2005-10-18Not applicableUs
Clarithromycintablet500 mg/1oralREMEDYREPACK INC.2011-04-20Not applicableUs
Clarithromycintablet, film coated500 mg/1oralApotex Corp2007-09-13Not applicableUs
Clarithromycintablet500 mg/1oralPreferred Pharmaceuticals, Inc2005-10-05Not applicableUs
Clarithromycintablet, film coated, extended release500 mg/1oralTeva Pharmaceuticals USA Inc2006-06-23Not applicableUs
Clarithromycintablet, film coated250 mg/1oralAidarex Pharmaceuticals LLC2006-05-31Not applicableUs
Clarithromycintablet, film coated500 mg/1oralREMEDYREPACK INC.2014-03-03Not applicableUs
Clarithromycintablet250 mg/1oralbryant ranch prepack2005-10-18Not applicableUs
Clarithromycintablet, film coated250 mg/1oralLannett Company, Inc.2015-12-04Not applicableUs
Clarithromycintablet, film coated, extended release500 mg/1oralPd Rx Pharmaceuticals, Inc.2008-01-01Not applicableUs
Clarithromycintablet, film coated500 mg/1oralWockhardt Limited2006-05-31Not applicableUs
Clarithromycintablet, film coated500 mg/1oralAurobindo Pharma Limited2012-07-25Not applicableUs
Clarithromycintablet, film coated, extended release500 mg/1oralDepartment Of State Health Services, Pharmacy Branch2008-01-01Not applicableUs
Clarithromycintablet, coated500 mg/1oralRoxane Laboratories, Inc2004-05-25Not applicableUs
Clarithromycintablet250 mg/1oralRebel Distributors Corp.2005-10-18Not applicableUs
Clarithromycintablet, film coated250 mg/1oralREMEDYREPACK INC.2011-05-12Not applicableUs
Clarithromycingranule, for suspension250 mg/5mLoralRanbaxy Pharmaceuticals Inc.2007-10-03Not applicableUs
Clarithromycintablet, film coated500 mg/1oralBlenheim Pharmacal, Inc.2012-10-05Not applicableUs
Clarithromycintablet500 mg/1oralSandoz Inc2005-08-25Not applicableUs
Clarithromycintablet, film coated500 mg/1oralREMEDYREPACK INC.2011-05-04Not applicableUs
Clarithromycintablet, film coated250 mg/1oralApotex Corp2007-09-13Not applicableUs
Clarithromycintablet500 mg/1oralLife Line Home Care Services, Inc.2011-12-08Not applicableUs
Clarithromycintablet, film coated250 mg/1oralTeva Pharmaceuticals USA Inc2014-12-16Not applicableUs
Clarithromycintablet, film coated500 mg/1oralRebel Distributors Corp2006-05-31Not applicableUs
Clarithromycinfor suspension250 mg/5mLoralPhysicians Total Care, Inc.2008-03-04Not applicableUs
Clarithromycintablet, film coated500 mg/1oralWockhardt USA LLC.2006-05-31Not applicableUs
Clarithromycintablet, film coated500 mg/1oralLannett Company, Inc.2015-12-04Not applicableUs
Clarithromycintablet, film coated500 mg/1oralSunshine Lake Pharma Co., Ltd.2015-09-29Not applicableUs
Clarithromycintablet, film coated250 mg/1oralWockhardt Limited2006-05-31Not applicableUs
Clarithromycintablet, film coated, extended release500 mg/1oralDispensing Solutions, Inc.2008-01-01Not applicableUs
Clarithromycintablet, film coated250 mg/1oralCitron Pharma LLC2012-07-25Not applicableUs
Clarithromycintablet, film coated250 mg/1oralTeva Pharmaceuticals USA Inc2005-06-28Not applicableUs
Clarithromycintablet500 mg/1oralRebel Distributors Corp.2005-08-25Not applicableUs
Clarithromycintablet, film coated500 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-11-15Not applicableUs
Clarithromycintablet, extended release500 mg/1oralbryant ranch prepack2009-05-30Not applicableUs
Clarithromycintablet250 mg/1oralAvera Mc Kennan Hospital2015-05-01Not applicableUs
Clarithromycinfor suspension125 mg/5mLoralSandoz Inc2007-09-04Not applicableUs
Clarithromycintablet250 mg/1oralREMEDYREPACK INC.2011-06-01Not applicableUs
Clarithromycintablet, film coated250 mg/1oralRanbaxy Pharmaceuticals Inc.2005-05-25Not applicableUs
Clarithromycintablet, film coated250 mg/1oralAllied Pharma Inc2012-12-31Not applicableUs
Clarithromycintablet, film coated500 mg/1oralProficient Rx LP2012-07-25Not applicableUs
Clarithromycintablet, film coated500 mg/1oralTeva Pharmaceuticals USA Inc2014-12-16Not applicableUs
Clarithromycintablet, film coated, extended release500 mg/1oralPd Rx Pharmaceuticals, Inc.2008-01-01Not applicableUs
Clarithromycintablet500 mg/1oralPhysicians Total Care, Inc.2005-10-05Not applicableUs
Clarithromycintablet, film coated250 mg/1oralWockhardt USA LLC.2006-05-31Not applicableUs
Clarithromycintablet, film coated, extended release500 mg/1oralActavis Pharma, Inc.2008-01-01Not applicableUs
Clarithromycintablet, film coated250 mg/1oralSunshine Lake Pharma Co., Ltd.2015-09-29Not applicableUs
Clarithromycintablet500 mg/1oralClinical Solutions Wholesale2005-08-25Not applicableUs
Clarithromycintablet500 mg/1oralAmerican Health Packaging2014-04-16Not applicableUs
Clarithromycintablet, film coated500 mg/1oralCitron Pharma LLC2012-07-25Not applicableUs
Clarithromycintablet, film coated500 mg/1oralTeva Pharmaceuticals USA Inc2005-06-28Not applicableUs
Clarithromycintablet, film coated500 mg/1oralAidarex Pharmaceuticals LLC2006-05-31Not applicableUs
Clarithromycintablet, film coated500 mg/1oralREMEDYREPACK INC.2013-05-092016-04-05Us
Clarithromycintablet, coated500 mg/1oralbryant ranch prepack2004-05-25Not applicableUs
Clarithromycintablet, film coated500 mg/1oralAllied Pharma Inc2012-12-31Not applicableUs
Clarithromycinfor suspension250 mg/5mLoralSandoz Inc2007-09-04Not applicableUs
Clarithromycintablet250 mg/1oralREMEDYREPACK INC.2011-06-27Not applicableUs
Clarithromycintablet, film coated500 mg/1oralRanbaxy Pharmaceuticals Inc.2005-05-25Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Klacid XLNot Available
Klaricid XLNot Available
MacladinNot Available
NaxyNot Available
VeclamNot Available
ZeclarNot Available
Brand mixtures
NameLabellerIngredients
Hp-pacTakeda Pharmaceuticals America Inc
Lansoprazole, Amoxicillin, and ClarithromycinTeva Pharmaceuticals USA Inc
Omeclamox-pakPernix Therapeutics, LLC
SaltsNot Available
Categories
UNIIH1250JIK0A
CAS number81103-11-9
WeightAverage: 747.9534
Monoisotopic: 747.476891299
Chemical FormulaC38H69NO13
InChI KeyInChIKey=AGOYDEPGAOXOCK-KCBOHYOISA-N
InChI
InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
IUPAC Name
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-12,13-dihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
SMILES
[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[[email protected]](C)O1)O[[email protected]]1[[email protected]](C)[C@@H](O[C@]2([H])O[[email protected]](C)C[C@@H]([[email protected]]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[[email protected]](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as macrolides and analogues. These are organic compounds containing a lactone ring of at least twelve members.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassMacrolides and analogues
Sub ClassNot Available
Direct ParentMacrolides and analogues
Alternative Parents
Substituents
  • Macrolide
  • Amino sugar
  • Desosamine
  • Amino saccharide
  • Oxane
  • Monosaccharide
  • Tertiary alcohol
  • Cyclic ketone
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Lactone
  • Ketone
  • Carboxylic acid ester
  • 1,2-diol
  • 1,2-aminoalcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationAn alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, mild to moderate community-acquired pneuomia, Legionnaires' disease, and pertussis. Other indications include treatment of uncomplicated skin or skin structure infections, helicobacter pylori infection, duodenal ulcer disease, bartonella infections, early Lyme disease, and encephalitis caused by Toxoplasma gondii (in HIV infected patients in conjunction with pyrimethamine). Clarithromycin may also decrease the incidence of cryptosporidiosis, prevent the occurence of α-hemolytic (viridans group) streptococcal endocarditis, as well as serve as a primary prevention for Mycobacterium avium complex (MAC) bacteremia or disseminated infections (in adults, adolescents, and children with advanced HIV infection).
PharmacodynamicsClarithromycin is a macrolide antibiotic whose spectrum of activity includes many gram-positive (Staphylococcus aureus, S. pneumoniae, and S. pyogenes) and gram-negative aerobic bacteria (Haemophilus influenzae, H. parainfluenzae, and Moraxella catarrhalis), many anaerobic bacteria, some mycobacteria, and some other organisms including Mycoplasma, Ureaplasma, Chlamydia, Toxoplasma, and Borrelia. Other aerobic bacteria that clarithromycin has activity against include C. pneumoniae and M. pneumoniae. Clarithromycin has an in-vitro activity that is similar or greater than that of erythromycin against erythromycin-susceptible organisms. Clarithromycin is usually bacteriostatic, but may be bactericidal depending on the organism and the drug concentration.
Mechanism of actionClarithromycin is first metabolized to 14-OH clarithromycin, which is active and works synergistically with its parent compound. Like other macrolides, it then penetrates bacteria cell wall and reversibly binds to domain V of the 23S ribosomal RNA of the 50S subunit of the bacterial ribosome, blocking translocation of aminoacyl transfer-RNA and polypeptide synthesis. Clarithromycin also inhibits the hepatic microsomal CYP3A4 isoenzyme and P-glycoprotein, an energy-dependent drug efflux pump.
Related Articles
AbsorptionClarithromycin is well-absorbed, acid stable and may be taken with food.
Volume of distributionNot Available
Protein binding~ 70% protein bound
Metabolism

Hepatic - predominantly metabolized by CYP3A4 resulting in numerous drug interactions.

SubstrateEnzymesProduct
Clarithromycin
14-hydroxyclarithromycinDetails
Clarithromycin
N-desmethylclarithromycinDetails
Route of eliminationAfter a 250 mg tablet every 12 hours, approximately 20% of the dose is excreted in the urine as clarithromycin, while after a 500 mg tablet every 12 hours, the urinary excretion of clarithromycin is somewhat greater, approximately 30%.
Half life3-4 hours
ClearanceNot Available
ToxicitySymptoms of toxicity include diarrhea, nausea, abnormal taste, dyspepsia, and abdominal discomfort. Transient hearing loss with high doses has been observed. Pseudomembraneous colitis has been reported with clarithromycin use. Allergic reactions ranging from urticaria and mild skin eruptions to rare cases of anaphylaxis and Stevens-Johnson syndrome have also occurred. Rare cases of severe hepatic dysfunctions also have been reported. Hepatic failure is usually reversible, but fatalities have been reported. Clarithromycin may also cause tooth decolouration which may be removed by dental cleaning. Fetal abnormalities, such as cardiovascular defects, cleft palate and fetal growth retardation, have been observed in animals. Clarithromycin may cause QT prolongation.
Affected organisms
  • Enteric bacteria and other eubacteria
  • Mycobacterium
  • Streptococcus pyogenes
  • Streptococcus pneumoniae
  • Haemophilus influenzae
  • Helicobacter pylori
  • Mycobacterium leprae
  • Mycobacterium avium
Pathways
PathwayCategorySMPDB ID
Clarithromycin Action PathwayDrug actionSMP00248
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5434
Blood Brain Barrier-0.987
Caco-2 permeable-0.8674
P-glycoprotein substrateSubstrate0.7714
P-glycoprotein inhibitor IInhibitor0.8475
P-glycoprotein inhibitor IINon-inhibitor0.622
Renal organic cation transporterNon-inhibitor0.8987
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9161
CYP450 3A4 substrateSubstrate0.6672
CYP450 1A2 substrateNon-inhibitor0.8973
CYP450 2C9 inhibitorNon-inhibitor0.8851
CYP450 2D6 inhibitorNon-inhibitor0.9258
CYP450 2C19 inhibitorNon-inhibitor0.8835
CYP450 3A4 inhibitorNon-inhibitor0.5524
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.898
Ames testNon AMES toxic0.8967
CarcinogenicityNon-carcinogens0.9294
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7236 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9883
hERG inhibition (predictor II)Non-inhibitor0.9038
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Granules for suspensionoral125 mg
Granules for suspensionoral250 mg
Granule, for suspensionoral125 mg/5mL
Granule, for suspensionoral250 mg/5mL
Tablet, film coatedoral250 mg/1
Tablet, film coatedoral500 mg/1
Tablet, film coated, extended releaseoral500 mg/1
Tabletoral250 mg
Tablet (extended-release)oral500 mg
For suspensionoral125 mg/5mL
For suspensionoral250 mg/5mL
Tabletoral250 mg/1
Tabletoral500 mg/1
Tablet, coatedoral250 mg/1
Tablet, coatedoral500 mg/1
Tablet, extended releaseoral500 mg/1
Kit; capsule; capsule (sustained-release); tabletoral
Kit
Tabletoral500 mg
Prices
Unit descriptionCostUnit
Biaxin 60 250 mg tablet Bottle379.5USD bottle
Clarithromycin 250 mg/5ml Suspension 100ml Bottle86.23USD bottle
Clarithromycin 250 mg/5ml Suspension 50ml Bottle46.56USD bottle
Clarithromycin 125 mg/5ml Suspension 100ml Bottle45.24USD bottle
Clarithromycin 125 mg/5ml Suspension 50ml Bottle27.99USD bottle
Biaxin XL 500 mg 24 Hour tablet6.77USD tablet
Biaxin xl 500 mg tablet6.57USD tablet
Biaxin 250 mg tablet6.42USD tablet
Biaxin 500 mg tablet6.37USD tablet
Clarithromycin 500 mg 24 Hour tablet5.21USD tablet
Clarithromycin er 500 mg tablet5.01USD tablet
Clarithromycin 250 mg tablet4.61USD tablet
Clarithromycin 500 mg tablet4.61USD tablet
Biaxin Bid 500 mg Tablet3.41USD tablet
Biaxin Xl 500 mg Extended-Release Tablet2.63USD tablet
Mylan-Clarithromycin 500 mg Tablet1.91USD tablet
Pms-Clarithromycin 500 mg Tablet1.91USD tablet
Ratio-Clarithromycin 500 mg Tablet1.91USD tablet
Sandoz Clarithromycin 500 mg Tablet1.91USD tablet
Biaxin Bid 250 mg Tablet1.73USD tablet
Clarithromycin 100% powder1.56USD g
Biaxin 50 mg/ml Suspension0.59USD ml
Biaxin 25 mg/ml Suspension0.3USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1328609 No1994-04-192011-04-19Canada
CA2471102 No2005-02-082017-07-25Canada
US6010718 No1997-04-112017-04-11Us
US6551616 No1997-06-152017-06-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point220 dec °CPhysProp
water solubility0.33 mg/LNot Available
logP3.16MCFARLAND,JW ET AL. (1997)
pKa8.99 (at 25 °C)MCFARLAND,JW ET AL. (1997)
Predicted Properties
PropertyValueSource
Water Solubility0.217 mg/mLALOGPS
logP3.18ALOGPS
logP3.24ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)12.46ChemAxon
pKa (Strongest Basic)8.38ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area182.91 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity190.79 m3·mol-1ChemAxon
Polarizability82.03 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Jih-Hua Liu, David A. Riley, “Preparation of crystal form II of clarithromycin.” U.S. Patent US5844105, issued May, 1997.

US5844105
General References
  1. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H: Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet. 2007 Feb 10;369(9560):482-90. [PubMed:17292768 ]
  2. Zuckerman JM, Qamar F, Bono BR: Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am. 2009 Dec;23(4):997-1026, ix-x. doi: 10.1016/j.idc.2009.06.013. [PubMed:19909895 ]
  3. Piscitelli SC, Danziger LH, Rodvold KA: Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm. 1992 Feb;11(2):137-52. [PubMed:1312921 ]
  4. Peters DH, Clissold SP: Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1992 Jul;44(1):117-64. [PubMed:1379907 ]
  5. Authors unspecified: Clarithromycin. Tuberculosis (Edinb). 2008 Mar;88(2):92-5. doi: 10.1016/S1472-9792(08)70005-2. [PubMed:18486039 ]
  6. Stephenson GA, Stowell JG, Toma PH, Pfeiffer RR, Byrn SR: Solid-state investigations of erythromycin A dihydrate: structure, NMR spectroscopy, and hygroscopicity. J Pharm Sci. 1997 Nov;86(11):1239-44. [PubMed:9383733 ]
External Links
ATC CodesA02BD05A02BD06A02BD07A02BD04A02BD11J01FA09A02BD09
AHFS Codes
  • 08:12.12.92
PDB EntriesNot Available
FDA labelDownload (376 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with 3,4-Dichloroisocoumarin.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Clarithromycin.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Clarithromycin.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Clarithromycin.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Clarithromycin.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Clarithromycin.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Clarithromycin.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Clarithromycin.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Clarithromycin.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Clarithromycin.
AlbendazoleThe serum concentration of Clarithromycin can be increased when it is combined with Albendazole.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Clarithromycin.
AldosteroneThe serum concentration of Clarithromycin can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Clarithromycin.
AlectinibThe serum concentration of Clarithromycin can be increased when it is combined with Alectinib.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Clarithromycin.
AlfentanilThe serum concentration of Clarithromycin can be increased when it is combined with Alfentanil.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Clarithromycin.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Clarithromycin.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Clarithromycin.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Clarithromycin.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Clarithromycin.
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Clarithromycin.
AlogliptinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Alogliptin.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Clarithromycin.
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Clarithromycin.
Alpha-1-proteinase inhibitorThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Alpha-1-proteinase inhibitor.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Clarithromycin.
AmantadineAmantadine may increase the QTc-prolonging activities of Clarithromycin.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Clarithromycin.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Clarithromycin.
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Clarithromycin.
Aminohippuric acidThe serum concentration of Clarithromycin can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Clarithromycin.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Clarithromycin.
AmiodaroneClarithromycin may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe serum concentration of Clarithromycin can be decreased when it is combined with Amiodarone.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Clarithromycin.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Clarithromycin.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Clarithromycin.
AmlodipineThe serum concentration of Clarithromycin can be increased when it is combined with Amlodipine.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Clarithromycin.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Clarithromycin.
AmprenavirThe serum concentration of Clarithromycin can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Clarithromycin can be increased when it is combined with Amsacrine.
AnagrelideClarithromycin may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Clarithromycin.
Antithrombin III humanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Antithrombin III human.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Clarithromycin.
ApixabanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Apixaban.
ApomorphineApomorphine may increase the QTc-prolonging activities of Clarithromycin.
ApremilastThe metabolism of Apremilast can be decreased when combined with Clarithromycin.
AprepitantThe serum concentration of Clarithromycin can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Clarithromycin.
AprotininThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Aprotinin.
ArformoterolArformoterol may increase the QTc-prolonging activities of Clarithromycin.
ArgatrobanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Argatroban.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Clarithromycin.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Clarithromycin.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Clarithromycin.
ArmodafinilThe metabolism of Clarithromycin can be decreased when combined with Armodafinil.
Arsenic trioxideClarithromycin may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherClarithromycin may increase the QTc-prolonging activities of Artemether.
AsenapineClarithromycin may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Clarithromycin.
AsunaprevirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Asunaprevir.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Clarithromycin.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Clarithromycin.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Clarithromycin.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Clarithromycin.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Clarithromycin.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Clarithromycin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Clarithromycin.
AzelastineThe metabolism of Azelastine can be decreased when combined with Clarithromycin.
AzelastineThe serum concentration of Clarithromycin can be increased when it is combined with Azelastine.
AzithromycinClarithromycin may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Azithromycin.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Clarithromycin.
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Clarithromycin.
BatimastatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Batimastat.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Clarithromycin.
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Clarithromycin.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Clarithromycin.
BenazeprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Benazepril.
BenzamidineThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Benzamidine.
BenzocaineThe serum concentration of Clarithromycin can be increased when it is combined with Benzocaine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Clarithromycin.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Clarithromycin.
BepridilThe serum concentration of Clarithromycin can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Clarithromycin.
BexaroteneThe serum concentration of Clarithromycin can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Clarithromycin.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Clarithromycin.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Clarithromycin.
BiperidenThe serum concentration of Clarithromycin can be increased when it is combined with Biperiden.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Clarithromycin.
BivalirudinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Bivalirudin.
BoceprevirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Clarithromycin.
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Clarithromycin.
BortezomibBortezomib may increase the QTc-prolonging activities of Clarithromycin.
BosentanThe serum concentration of Clarithromycin can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Clarithromycin.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Clarithromycin.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Clarithromycin.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Clarithromycin.
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Clarithromycin.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Clarithromycin.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Clarithromycin.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Clarithromycin.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Clarithromycin.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Clarithromycin.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Clarithromycin.
BuprenorphineThe serum concentration of Clarithromycin can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Bupropion can be decreased when combined with Clarithromycin.
BuserelinBuserelin may increase the QTc-prolonging activities of Clarithromycin.
BuspironeThe metabolism of Buspirone can be decreased when combined with Clarithromycin.
BuspironeThe serum concentration of Clarithromycin can be increased when it is combined with Buspirone.
BusulfanThe metabolism of Busulfan can be decreased when combined with Clarithromycin.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Clarithromycin.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Clarithromycin.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Clarithromycin.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Clarithromycin.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Clarithromycin.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Clarithromycin.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Clarithromycin.
CandesartanThe serum concentration of Clarithromycin can be increased when it is combined with Candesartan.
CandoxatrilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Candoxatril.
CaptoprilThe serum concentration of Clarithromycin can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Clarithromycin can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Clarithromycin.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Clarithromycin.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Clarithromycin.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Clarithromycin.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Clarithromycin.
CarvedilolThe serum concentration of Clarithromycin can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Clarithromycin can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Clarithromycin.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Clarithromycin.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Clarithromycin.
CeritinibThe serum concentration of Clarithromycin can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Clarithromycin.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Clarithromycin.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Clarithromycin.
ChloramphenicolThe metabolism of Clarithromycin can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Clarithromycin.
ChloroquineClarithromycin may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe serum concentration of Clarithromycin can be increased when it is combined with Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Clarithromycin.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Clarithromycin.
ChlorpropamideThe serum concentration of Clarithromycin can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Clarithromycin can be increased when it is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Clarithromycin.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Clarithromycin.
CholesterolThe serum concentration of Clarithromycin can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Clarithromycin can be decreased when it is combined with Cholic Acid.
ChymostatinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Chymostatin.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Clarithromycin.
CilastatinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Cilastatin.
CilazaprilThe serum concentration of Clarithromycin can be increased when it is combined with Cilazapril.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Clarithromycin.
CimetidineThe serum concentration of Clarithromycin can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Clarithromycin.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Clarithromycin.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Clarithromycin.
CisaprideClarithromycin may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Clarithromycin.
CitalopramClarithromycin may increase the QTc-prolonging activities of Citalopram.
CitalopramThe serum concentration of Clarithromycin can be increased when it is combined with Citalopram.
ClemastineThe metabolism of Clarithromycin can be decreased when combined with Clemastine.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Clarithromycin.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Clarithromycin.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Clarithromycin.
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Clarithromycin.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Clarithromycin.
ClofazimineThe serum concentration of Clarithromycin can be increased when it is combined with Clofazimine.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Clarithromycin.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Clarithromycin.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Clarithromycin.
ClomipramineClomipramine may increase the QTc-prolonging activities of Clarithromycin.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Clarithromycin.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Clarithromycin.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Clarithromycin.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Clarithromycin.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Clarithromycin.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Clarithromycin.
ClotrimazoleThe metabolism of Clarithromycin can be decreased when combined with Clotrimazole.
ClozapineClozapine may increase the QTc-prolonging activities of Clarithromycin.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of Cobicistat can be increased when it is combined with Clarithromycin.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Clarithromycin.
CocaineThe metabolism of Cocaine can be decreased when combined with Clarithromycin.
CodeineThe metabolism of Codeine can be decreased when combined with Clarithromycin.
ColchicineThe serum concentration of Clarithromycin can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Clarithromycin can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Clarithromycin can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Clarithromycin.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Clarithromycin.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Clarithromycin.
CrizotinibThe metabolism of Clarithromycin can be decreased when combined with Crizotinib.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Clarithromycin.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Clarithromycin.
CyclophosphamideThe serum concentration of Clarithromycin can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Clarithromycin can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Clarithromycin.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Clarithromycin.
Dabigatran etexilateThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Dabigatran etexilate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Clarithromycin.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Clarithromycin.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Clarithromycin.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Clarithromycin.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Clarithromycin.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Clarithromycin.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Clarithromycin.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Clarithromycin.
DapsoneThe metabolism of Dapsone can be decreased when combined with Clarithromycin.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Clarithromycin.
DarunavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Darunavir.
DarunavirThe metabolism of Darunavir can be decreased when combined with Clarithromycin.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Clarithromycin.
DasatinibThe serum concentration of Clarithromycin can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Clarithromycin can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Clarithromycin.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Clarithromycin.
DeferasiroxThe serum concentration of Clarithromycin can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Clarithromycin.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Clarithromycin.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Clarithromycin.
DelavirdineThe metabolism of Clarithromycin can be decreased when combined with Delavirdine.
DesfluraneDesflurane may increase the QTc-prolonging activities of Clarithromycin.
DesipramineDesipramine may increase the QTc-prolonging activities of Clarithromycin.
DesloratadineThe serum concentration of Clarithromycin can be increased when it is combined with Desloratadine.
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Clarithromycin.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Clarithromycin.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Clarithromycin.
DexamethasoneThe serum concentration of Clarithromycin can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Clarithromycin.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Clarithromycin.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Clarithromycin.
DextromethorphanThe serum concentration of Clarithromycin can be increased when it is combined with Dextromethorphan.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Clarithromycin.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Clarithromycin.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Clarithromycin.
DiclofenacThe serum concentration of Clarithromycin can be increased when it is combined with Diclofenac.
DienogestThe serum concentration of Dienogest can be increased when it is combined with Clarithromycin.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Clarithromycin.
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Clarithromycin.
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Clarithromycin.
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Clarithromycin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Clarithromycin.
DigoxinThe serum concentration of Clarithromycin can be decreased when it is combined with Digoxin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Clarithromycin.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Clarithromycin.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Clarithromycin.
DihydroergotamineThe metabolism of Clarithromycin can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Clarithromycin.
DiltiazemThe metabolism of Clarithromycin can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Clarithromycin.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Clarithromycin.
DipyridamoleThe serum concentration of Clarithromycin can be increased when it is combined with Dipyridamole.
DisopyramideClarithromycin may increase the QTc-prolonging activities of Disopyramide.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Clarithromycin.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Clarithromycin.
DofetilideClarithromycin may increase the QTc-prolonging activities of Dofetilide.
DolasetronDolasetron may increase the QTc-prolonging activities of Clarithromycin.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Clarithromycin.
DonepezilThe metabolism of Donepezil can be decreased when combined with Clarithromycin.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Clarithromycin.
DoxazosinThe serum concentration of Clarithromycin can be increased when it is combined with Doxazosin.
DoxepinDoxepin may increase the QTc-prolonging activities of Clarithromycin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Clarithromycin.
DoxorubicinThe serum concentration of Clarithromycin can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Clarithromycin.
DoxycyclineThe metabolism of Clarithromycin can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Clarithromycin.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Clarithromycin.
DronedaroneThe metabolism of Clarithromycin can be decreased when combined with Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Clarithromycin.
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Clarithromycin.
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Clarithromycin.
EcabetThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ecabet.
EdoxabanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Edoxaban.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Clarithromycin.
EfavirenzThe serum concentration of Clarithromycin can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Clarithromycin.
ElafinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Elafin.
ElbasvirThe serum concentration of Clarithromycin can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Clarithromycin.
EliglustatClarithromycin may increase the QTc-prolonging activities of Eliglustat.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Clarithromycin.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Clarithromycin.
EnalaprilThe serum concentration of Clarithromycin can be increased when it is combined with Enalapril.
EnalaprilatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Enalaprilat.
EnalkirenThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Enalkiren.
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Clarithromycin.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Clarithromycin.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Clarithromycin.
EquileninThe serum concentration of Equilenin can be increased when it is combined with Clarithromycin.
EquilinThe serum concentration of Equilin can be increased when it is combined with Clarithromycin.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Clarithromycin.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Clarithromycin.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Clarithromycin.
ErgonovineThe serum concentration of Clarithromycin can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Clarithromycin.
EribulinEribulin may increase the QTc-prolonging activities of Clarithromycin.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Clarithromycin.
ErythromycinThe metabolism of Clarithromycin can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Clarithromycin.
EscitalopramClarithromycin may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Clarithromycin can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Clarithromycin.
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Clarithromycin.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Clarithromycin.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Clarithromycin.
EstramustineThe metabolism of Estramustine can be decreased when combined with Clarithromycin.
EstramustineThe serum concentration of Clarithromycin can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Clarithromycin can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Clarithromycin.
EstroneThe serum concentration of Clarithromycin can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Clarithromycin.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Clarithromycin.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Clarithromycin.
EthanolThe metabolism of Ethanol can be decreased when combined with Clarithromycin.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Clarithromycin.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Clarithromycin.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Clarithromycin.
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Clarithromycin.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Clarithromycin.
EtoposideThe serum concentration of Clarithromycin can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Clarithromycin.
EtravirineThe serum concentration of Clarithromycin can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Clarithromycin.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Clarithromycin.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Clarithromycin.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Clarithromycin.
EzogabineEzogabine may increase the QTc-prolonging activities of Clarithromycin.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Clarithromycin.
FamotidineFamotidine may increase the QTc-prolonging activities of Clarithromycin.
FelbamateFelbamate may increase the QTc-prolonging activities of Clarithromycin.
FelbamateThe metabolism of Felbamate can be decreased when combined with Clarithromycin.
FelodipineThe metabolism of Felodipine can be decreased when combined with Clarithromycin.
FelodipineThe serum concentration of Clarithromycin can be increased when it is combined with Felodipine.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Clarithromycin.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Clarithromycin.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Clarithromycin.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Clarithromycin.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Clarithromycin.
FinasterideThe metabolism of Finasteride can be decreased when combined with Clarithromycin.
FingolimodFingolimod may increase the QTc-prolonging activities of Clarithromycin.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Clarithromycin.
FlecainideFlecainide may increase the QTc-prolonging activities of Clarithromycin.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Clarithromycin.
FluconazoleFluconazole may increase the QTc-prolonging activities of Clarithromycin.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Clarithromycin.
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Clarithromycin.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Clarithromycin.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Clarithromycin.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Clarithromycin.
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Clarithromycin.
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Clarithromycin.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Clarithromycin.
FluoxetineClarithromycin may increase the QTc-prolonging activities of Fluoxetine.
FluoxetineThe serum concentration of Clarithromycin can be increased when it is combined with Fluoxetine.
FlupentixolClarithromycin may increase the QTc-prolonging activities of Flupentixol.
FlupentixolThe serum concentration of Clarithromycin can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Clarithromycin can be increased when it is combined with Fluphenazine.
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Clarithromycin.
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Clarithromycin.
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Clarithromycin.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Clarithromycin.
FlurazepamThe serum concentration of Clarithromycin can be increased when it is combined with Flurazepam.
FlutamideThe metabolism of Flutamide can be decreased when combined with Clarithromycin.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Clarithromycin.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Clarithromycin.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Clarithromycin.
FluvoxamineThe metabolism of Clarithromycin can be decreased when combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Clarithromycin.
FosamprenavirThe metabolism of Clarithromycin can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Clarithromycin can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Clarithromycin.
FosinoprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Fosinopril.
FosphenytoinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Fosphenytoin.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Clarithromycin.
Fusidic AcidThe serum concentration of Clarithromycin can be increased when it is combined with Fusidic Acid.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Clarithromycin.
GalantamineGalantamine may increase the QTc-prolonging activities of Clarithromycin.
GalantamineThe metabolism of Galantamine can be decreased when combined with Clarithromycin.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Clarithromycin.
GeldanamycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Clarithromycin.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Clarithromycin.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Clarithromycin.
GenisteinThe serum concentration of Clarithromycin can be increased when it is combined with Genistein.
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Clarithromycin.
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Clarithromycin.
GlycerolThe serum concentration of Clarithromycin can be increased when it is combined with Glycerol.
GM6001The therapeutic efficacy of Clarithromycin can be decreased when used in combination with GM6001.
GoserelinGoserelin may increase the QTc-prolonging activities of Clarithromycin.
Gramicidin DThe serum concentration of Clarithromycin can be increased when it is combined with Gramicidin D.
GranisetronGranisetron may increase the QTc-prolonging activities of Clarithromycin.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Clarithromycin.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Clarithromycin.
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Clarithromycin.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Clarithromycin.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Clarithromycin.
HalothaneThe metabolism of Halothane can be decreased when combined with Clarithromycin.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Clarithromycin.
HirulogThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Hirulog.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Clarithromycin.
HistrelinHistrelin may increase the QTc-prolonging activities of Clarithromycin.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Clarithromycin.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Clarithromycin.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Clarithromycin.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Clarithromycin.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Clarithromycin.
IbandronateIbandronate may increase the QTc-prolonging activities of Clarithromycin.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Clarithromycin.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Clarithromycin.
IbutilideClarithromycin may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Clarithromycin can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Clarithromycin resulting in a loss in efficacy.
IloperidoneClarithromycin may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Clarithromycin.
ImatinibThe metabolism of Clarithromycin can be decreased when combined with Imatinib.
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Clarithromycin.
ImipramineImipramine may increase the QTc-prolonging activities of Clarithromycin.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Clarithromycin.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Clarithromycin.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Clarithromycin.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Clarithromycin.
IndapamideIndapamide may increase the QTc-prolonging activities of Clarithromycin.
IndapamideThe metabolism of Indapamide can be decreased when combined with Clarithromycin.
IndinavirThe serum concentration of Clarithromycin can be decreased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Clarithromycin.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Clarithromycin.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Clarithromycin.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Clarithromycin.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Clarithromycin.
IsavuconazoniumThe metabolism of Clarithromycin can be decreased when combined with Isavuconazonium.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Clarithromycin.
IsoflurophateThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Isoflurophate.
IsoniazidThe metabolism of Clarithromycin can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Clarithromycin.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Clarithromycin.
IsradipineIsradipine may increase the QTc-prolonging activities of Clarithromycin.
IsradipineThe metabolism of Isradipine can be decreased when combined with Clarithromycin.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Clarithromycin.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Clarithromycin.
IvabradineIvabradine may increase the QTc-prolonging activities of Clarithromycin.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Clarithromycin.
IvacaftorThe serum concentration of Clarithromycin can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Clarithromycin.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Clarithromycin.
IxazomibThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ixazomib.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Clarithromycin.
KetamineThe metabolism of Ketamine can be decreased when combined with Clarithromycin.
KetamineThe serum concentration of Clarithromycin can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Clarithromycin.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Clarithromycin.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Clarithromycin.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Clarithromycin.
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Clarithromycin.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Clarithromycin.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Clarithromycin.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Clarithromycin.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Clarithromycin.
LapatinibLapatinib may increase the QTc-prolonging activities of Clarithromycin.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Clarithromycin.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Clarithromycin.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Clarithromycin.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Clarithromycin.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Clarithromycin.
LepirudinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Lepirudin.
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Clarithromycin.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Clarithromycin.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Clarithromycin.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Clarithromycin.
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Clarithromycin.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Clarithromycin.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Clarithromycin.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Clarithromycin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Clarithromycin.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Clarithromycin.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Clarithromycin.
LevothyroxineThe serum concentration of Clarithromycin can be decreased when it is combined with Levothyroxine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Clarithromycin.
LidocaineThe serum concentration of Clarithromycin can be increased when it is combined with Lidocaine.
LinagliptinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Linagliptin.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Clarithromycin.
LiothyronineThe serum concentration of Clarithromycin can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Clarithromycin can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Clarithromycin can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Clarithromycin.
LithiumLithium may increase the QTc-prolonging activities of Clarithromycin.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Clarithromycin.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Clarithromycin.
LopinavirClarithromycin may increase the QTc-prolonging activities of Lopinavir.
LopinavirThe serum concentration of Clarithromycin can be increased when it is combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Clarithromycin.
LoratadineThe serum concentration of Clarithromycin can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Clarithromycin.
LosartanThe serum concentration of Losartan can be increased when it is combined with Clarithromycin.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Clarithromycin.
LovastatinThe metabolism of Clarithromycin can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Clarithromycin can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Clarithromycin can be decreased when it is combined with Lumacaftor.
LumefantrineClarithromycin may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Clarithromycin.
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Clarithromycin.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Clarithromycin.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Clarithromycin.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Clarithromycin.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Clarithromycin.
MebendazoleThe serum concentration of Clarithromycin can be increased when it is combined with Mebendazole.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Clarithromycin.
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Clarithromycin.
MefloquineMefloquine may increase the QTc-prolonging activities of Clarithromycin.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Clarithromycin.
Megestrol acetateThe serum concentration of Clarithromycin can be increased when it is combined with Megestrol acetate.
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Clarithromycin.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Clarithromycin.
MeprobamateThe serum concentration of Clarithromycin can be increased when it is combined with Meprobamate.
MethadoneClarithromycin may increase the QTc-prolonging activities of Methadone.
MethadoneThe serum concentration of Clarithromycin can be increased when it is combined with Methadone.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Clarithromycin.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Clarithromycin.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Clarithromycin.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Clarithromycin.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Clarithromycin.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Clarithromycin.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Clarithromycin.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Clarithromycin.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Clarithromycin.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Clarithromycin.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Clarithromycin.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Clarithromycin.
MianserinThe metabolism of Mianserin can be decreased when combined with Clarithromycin.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Clarithromycin.
MibefradilThe serum concentration of Clarithromycin can be increased when it is combined with Mibefradil.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Clarithromycin.
MiconazoleThe serum concentration of Clarithromycin can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Clarithromycin can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Clarithromycin.
MifepristoneMifepristone may increase the QTc-prolonging activities of Clarithromycin.
MirabegronMirabegron may increase the QTc-prolonging activities of Clarithromycin.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Clarithromycin.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Clarithromycin.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Clarithromycin.
MitomycinThe serum concentration of Clarithromycin can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Clarithromycin can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Clarithromycin can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Clarithromycin.
MoclobemideThe metabolism of Clarithromycin can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Clarithromycin can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Clarithromycin.
MoexiprilMoexipril may increase the QTc-prolonging activities of Clarithromycin.
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Clarithromycin.
MontelukastThe metabolism of Montelukast can be decreased when combined with Clarithromycin.
MorphineThe serum concentration of Morphine can be increased when it is combined with Clarithromycin.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Clarithromycin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Clarithromycin.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NadololThe serum concentration of Nadolol can be increased when it is combined with Clarithromycin.
NafcillinThe serum concentration of Clarithromycin can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Clarithromycin.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Clarithromycin.
NaltrexoneThe serum concentration of Clarithromycin can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Clarithromycin can be increased when it is combined with Naringenin.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Clarithromycin.
NCX 4016The therapeutic efficacy of Clarithromycin can be decreased when used in combination with NCX 4016.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Clarithromycin.
NefazodoneThe serum concentration of Clarithromycin can be decreased when it is combined with Nefazodone.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Clarithromycin.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Clarithromycin.
NeostigmineThe serum concentration of Clarithromycin can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Clarithromycin can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Clarithromycin can be decreased when combined with Nevirapine.
NicardipineNicardipine may increase the QTc-prolonging activities of Clarithromycin.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Clarithromycin.
NicotineThe metabolism of Nicotine can be decreased when combined with Clarithromycin.
NifedipineThe serum concentration of Clarithromycin can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Clarithromycin.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Clarithromycin.
NilotinibThe metabolism of Clarithromycin can be decreased when combined with Nilotinib.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Clarithromycin.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Clarithromycin.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Clarithromycin.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Clarithromycin.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Clarithromycin.
NitrazepamThe serum concentration of Clarithromycin can be increased when it is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Clarithromycin.
NitrendipineThe serum concentration of Clarithromycin can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Clarithromycin.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Clarithromycin.
NorethisteroneThe serum concentration of Clarithromycin can be decreased when it is combined with Norethisterone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Clarithromycin.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Clarithromycin.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Clarithromycin.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Clarithromycin.
OctreotideOctreotide may increase the QTc-prolonging activities of Clarithromycin.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Clarithromycin.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Clarithromycin.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Clarithromycin.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Clarithromycin.
OlaparibThe metabolism of Clarithromycin can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Clarithromycin.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Clarithromycin.
OmapatrilatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Clarithromycin.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Clarithromycin.
OmeprazoleThe serum concentration of Clarithromycin can be increased when it is combined with Omeprazole.
OndansetronOndansetron may increase the QTc-prolonging activities of Clarithromycin.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Clarithromycin.
OsimertinibThe serum concentration of Clarithromycin can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Clarithromycin.
OtamixabanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Otamixaban.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Clarithromycin.
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Clarithromycin.
OxycodoneThe risk or severity of adverse effects can be increased when Clarithromycin is combined with Oxycodone.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Clarithromycin.
OxytocinOxytocin may increase the QTc-prolonging activities of Clarithromycin.
P-NitrophenolThe serum concentration of Clarithromycin can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Clarithromycin can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Clarithromycin can be increased when it is combined with Palbociclib.
PaliperidoneClarithromycin may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Clarithromycin can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Clarithromycin.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Clarithromycin.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Clarithromycin.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Clarithromycin.
PantoprazoleThe serum concentration of Clarithromycin can be increased when it is combined with Pantoprazole.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Clarithromycin.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Clarithromycin.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Clarithromycin.
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Clarithromycin.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Clarithromycin.
ParoxetineParoxetine may increase the QTc-prolonging activities of Clarithromycin.
PasireotidePasireotide may increase the QTc-prolonging activities of Clarithromycin.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Clarithromycin.
PazopanibPazopanib may increase the QTc-prolonging activities of Clarithromycin.
PentamidinePentamidine may increase the QTc-prolonging activities of Clarithromycin.
PentobarbitalThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Pentobarbital.
PerampanelThe metabolism of Perampanel can be decreased when combined with Clarithromycin.
PerflutrenPerflutren may increase the QTc-prolonging activities of Clarithromycin.
PergolideThe metabolism of Pergolide can be decreased when combined with Clarithromycin.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Clarithromycin.
PerindoprilThe serum concentration of Clarithromycin can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be decreased when combined with Clarithromycin.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Clarithromycin.
PethidineThe metabolism of Pethidine can be decreased when combined with Clarithromycin.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Clarithromycin.
PhenobarbitalThe serum concentration of Clarithromycin can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Clarithromycin.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Clarithromycin.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Clarithromycin.
PhenytoinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Clarithromycin.
PhosphoramidonThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Phosphoramidon.
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Clarithromycin.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Clarithromycin.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Clarithromycin.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Clarithromycin.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Clarithromycin.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Clarithromycin.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Clarithromycin.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Clarithromycin.
Platelet Activating FactorThe serum concentration of Clarithromycin can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Clarithromycin.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Clarithromycin.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Clarithromycin.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Clarithromycin.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Clarithromycin.
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Clarithromycin.
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Clarithromycin resulting in a loss in efficacy.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Clarithromycin.
PrazepamThe metabolism of Prazepam can be decreased when combined with Clarithromycin.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Clarithromycin.
PrazosinThe serum concentration of Clarithromycin can be increased when it is combined with Prazosin.
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Clarithromycin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Clarithromycin.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Clarithromycin.
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Clarithromycin.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Clarithromycin.
PrimidoneThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Primidone.
PrinomastatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Prinomastat.
ProbenecidThe serum concentration of Clarithromycin can be increased when it is combined with Probenecid.
ProcainamideClarithromycin may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Clarithromycin.
ProgesteroneThe serum concentration of Clarithromycin can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Clarithromycin.
ProguanilThe metabolism of Proguanil can be decreased when combined with Clarithromycin.
PromazinePromazine may increase the QTc-prolonging activities of Clarithromycin.
PromethazinePromethazine may increase the QTc-prolonging activities of Clarithromycin.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Clarithromycin.
PropofolPropofol may increase the QTc-prolonging activities of Clarithromycin.
PropofolThe metabolism of Propofol can be decreased when combined with Clarithromycin.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Clarithromycin.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Clarithromycin.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Clarithromycin.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Clarithromycin.
QuazepamThe metabolism of Quazepam can be decreased when combined with Clarithromycin.
QuercetinThe serum concentration of Clarithromycin can be increased when it is combined with Quercetin.
QuetiapineClarithromycin may increase the QTc-prolonging activities of Quetiapine.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Clarithromycin.
QuinacrineThe serum concentration of Clarithromycin can be increased when it is combined with Quinacrine.
QuinaprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Quinapril.
QuinidineClarithromycin may increase the QTc-prolonging activities of Quinidine.
QuinidineThe serum concentration of Clarithromycin can be increased when it is combined with Quinidine.
QuinineClarithromycin may increase the QTc-prolonging activities of Quinine.
QuinineThe serum concentration of Clarithromycin can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Clarithromycin.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Clarithromycin.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Clarithromycin.
RamiprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ramipril.
RanitidineThe serum concentration of Clarithromycin can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Clarithromycin can be increased when it is combined with Ranolazine.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Clarithromycin.
ReboxetineThe serum concentration of Clarithromycin can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Clarithromycin.
RemikirenThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Remikiren.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Clarithromycin.
ReserpineThe serum concentration of Clarithromycin can be decreased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Clarithromycin.
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Clarithromycin.
RifabutinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Rifabutin.
RifabutinThe metabolism of Rifabutin can be decreased when combined with Clarithromycin.
RifampicinThe serum concentration of Clarithromycin can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Clarithromycin.
RifapentineThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Clarithromycin.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Clarithromycin.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Clarithromycin.
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Clarithromycin.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Clarithromycin.
RiociguatThe metabolism of Riociguat can be decreased when combined with Clarithromycin.
RisperidoneRisperidone may increase the QTc-prolonging activities of Clarithromycin.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Clarithromycin.
RitonavirRitonavir may increase the QTc-prolonging activities of Clarithromycin.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Clarithromycin.
RivaroxabanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Rivaroxaban.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Clarithromycin.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Clarithromycin.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Clarithromycin.
RolapitantThe serum concentration of Clarithromycin can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Clarithromycin.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Clarithromycin.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Clarithromycin.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Clarithromycin.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Clarithromycin.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Clarithromycin.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Clarithromycin.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Clarithromycin.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Clarithromycin.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Clarithromycin.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Clarithromycin.
SaquinavirThe serum concentration of Clarithromycin can be decreased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Clarithromycin.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Clarithromycin.
SaxagliptinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Saxagliptin.
ScopolamineThe serum concentration of Clarithromycin can be increased when it is combined with Scopolamine.
SelegilineThe metabolism of Selegiline can be decreased when combined with Clarithromycin.
SelegilineThe serum concentration of Clarithromycin can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Clarithromycin.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Clarithromycin.
SertindoleThe metabolism of Sertindole can be decreased when combined with Clarithromycin.
SertralineSertraline may increase the QTc-prolonging activities of Clarithromycin.
SertralineThe metabolism of Sertraline can be decreased when combined with Clarithromycin.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Clarithromycin.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Clarithromycin.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Clarithromycin.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Clarithromycin.
SildenafilThe metabolism of Clarithromycin can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Clarithromycin.
SiltuximabThe serum concentration of Clarithromycin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Clarithromycin can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Clarithromycin.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Clarithromycin.
SirolimusThe serum concentration of Clarithromycin can be decreased when it is combined with Sirolimus.
SitagliptinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Sitagliptin.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Clarithromycin.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Clarithromycin.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Clarithromycin.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Clarithromycin.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Clarithromycin.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Clarithromycin.
SorafenibSorafenib may increase the QTc-prolonging activities of Clarithromycin.
SotalolClarithromycin may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Clarithromycin.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Clarithromycin.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Clarithromycin.
SpiraprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Spirapril.
SpironolactoneThe serum concentration of Clarithromycin can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Clarithromycin can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Clarithromycin can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Clarithromycin can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Clarithromycin can be decreased when it is combined with Streptozocin.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Clarithromycin.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Clarithromycin.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Clarithromycin.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Clarithromycin.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Clarithromycin.
SulfinpyrazoneThe serum concentration of Clarithromycin can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleClarithromycin may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Clarithromycin can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Clarithromycin can be increased when it is combined with Sumatriptan.
SunitinibSunitinib may increase the QTc-prolonging activities of Clarithromycin.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Clarithromycin.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Clarithromycin.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Clarithromycin.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Clarithromycin.
TacrineThe serum concentration of Clarithromycin can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Clarithromycin can be decreased when it is combined with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Clarithromycin.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Clarithromycin.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Clarithromycin.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Clarithromycin.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Clarithromycin.
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Clarithromycin.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Clarithromycin.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Clarithromycin.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Clarithromycin.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Clarithromycin.
TelaprevirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Clarithromycin.
TelavancinClarithromycin may increase the QTc-prolonging activities of Telavancin.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Clarithromycin.
TelmisartanThe serum concentration of Clarithromycin can be increased when it is combined with Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Clarithromycin.
TemocaprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Clarithromycin.
TeniposideThe metabolism of Teniposide can be decreased when combined with Clarithromycin.
TerazosinThe serum concentration of Clarithromycin can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Clarithromycin.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Clarithromycin.
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Clarithromycin.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Clarithromycin.
TesmilifeneThe serum concentration of Clarithromycin can be decreased when it is combined with Tesmilifene.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Clarithromycin.
TestosteroneThe serum concentration of Clarithromycin can be increased when it is combined with Testosterone.
TetrabenazineClarithromycin may increase the QTc-prolonging activities of Tetrabenazine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Clarithromycin.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Clarithromycin.
ThioridazineClarithromycin may increase the QTc-prolonging activities of Thioridazine.
ThiorphanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Thiorphan.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Clarithromycin.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Clarithromycin.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Clarithromycin.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Clarithromycin resulting in a loss in efficacy.
TicagrelorThe serum concentration of Clarithromycin can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Clarithromycin can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Clarithromycin.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Clarithromycin.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Clarithromycin.
TipranavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Clarithromycin.
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Clarithromycin.
TizanidineTizanidine may increase the QTc-prolonging activities of Clarithromycin.
TocilizumabThe serum concentration of Clarithromycin can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Clarithromycin.
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Clarithromycin.
TolterodineTolterodine may increase the QTc-prolonging activities of Clarithromycin.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Clarithromycin.
TopiramateThe metabolism of Clarithromycin can be decreased when combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Clarithromycin.
ToremifeneThe risk or severity of adverse effects can be increased when Clarithromycin is combined with Toremifene.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Clarithromycin.
TramadolThe serum concentration of Tramadol can be increased when it is combined with Clarithromycin.
TrandolaprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Trandolapril.
TranylcypromineThe metabolism of Clarithromycin can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Clarithromycin.
TrazodoneTrazodone may increase the QTc-prolonging activities of Clarithromycin.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Clarithromycin.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Clarithromycin.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Clarithromycin.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Clarithromycin.
TriazolamThe metabolism of Triazolam can be decreased when combined with Clarithromycin.
TrifluoperazineThe serum concentration of Clarithromycin can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Clarithromycin can be increased when it is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Clarithromycin.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Clarithromycin.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Clarithromycin.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Clarithromycin.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Clarithromycin.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Clarithromycin.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Clarithromycin.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Clarithromycin.
TroleandomycinThe serum concentration of Clarithromycin can be increased when it is combined with Troleandomycin.
UbenimexThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ubenimex.
UdenafilThe metabolism of Udenafil can be decreased when combined with Clarithromycin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Clarithromycin.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Clarithromycin.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Clarithromycin.
VandetanibClarithromycin may increase the QTc-prolonging activities of Vandetanib.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Clarithromycin.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Clarithromycin.
VardenafilVardenafil may increase the QTc-prolonging activities of Clarithromycin.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Clarithromycin.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Clarithromycin.
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Clarithromycin.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Clarithromycin.
VerapamilThe metabolism of Clarithromycin can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Clarithromycin.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Clarithromycin.
VilanterolVilanterol may increase the QTc-prolonging activities of Clarithromycin.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Clarithromycin.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Clarithromycin.
VildagliptinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Vildagliptin.
VinblastineThe serum concentration of Clarithromycin can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Clarithromycin.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Clarithromycin.
VincristineThe serum concentration of Clarithromycin can be decreased when it is combined with Vincristine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Clarithromycin.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Clarithromycin.
VinorelbineThe serum concentration of Clarithromycin can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Clarithromycin.
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Clarithromycin.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Clarithromycin.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Clarithromycin.
VorinostatVorinostat may increase the QTc-prolonging activities of Clarithromycin.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Clarithromycin.
WarfarinThe metabolism of Warfarin can be decreased when combined with Clarithromycin.
XimelagatranThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ximelagatran.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Clarithromycin.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Clarithromycin.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Clarithromycin.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Clarithromycin.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Clarithromycin.
ZileutonThe metabolism of Zileuton can be decreased when combined with Clarithromycin.
ZimelidineThe serum concentration of Clarithromycin can be increased when it is combined with Zimelidine.
ZiprasidoneClarithromycin may increase the QTc-prolonging activities of Ziprasidone.
ZiprasidoneThe metabolism of Clarithromycin can be decreased when combined with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Clarithromycin.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Clarithromycin.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Clarithromycin.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Clarithromycin.
ZuclopenthixolClarithromycin may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Biaxin - take without regard to meals (however absorption appears to be improved when drug is taken with food).
  • Biaxin XL - take with a meal, taking it on an empty stomach is associated with total product exposure 30% inferior to that observed when administered with food.

Targets

Kind
Protein
Organism
Shigella flexneri
Pharmacological action
yes
Actions
inhibitor
General Function:
Structural constituent of ribosome
Specific Function:
Protein L10 is also a translational repressor protein. It controls the translation of the rplJL-rpoBC operon by binding to its mRNA (By similarity).Forms part of the ribosomal stalk, playing a central role in the interaction of the ribosome with GTP-bound translation factors.
Gene Name:
rplJ
Uniprot ID:
P0A7J6
Molecular Weight:
17711.38 Da
References
  1. Morimura T, Hashiba M, Kameda H, Takami M, Takahama H, Ohshige M, Sugawara F: Identification of macrolide antibiotic-binding Human_p8 protein. J Antibiot (Tokyo). 2008 May;61(5):291-6. doi: 10.1038/ja.2008.41. [PubMed:18653994 ]
  2. Champney WS, Burdine R: Macrolide antibiotic inhibition of translation and 50S ribosomal subunit assembly in methicillin-resistant Staphylococcus aureus cells. Microb Drug Resist. 1998 Fall;4(3):169-74. [PubMed:9818968 ]
  3. Zuckerman JM, Qamar F, Bono BR: Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am. 2009 Dec;23(4):997-1026, ix-x. doi: 10.1016/j.idc.2009.06.013. [PubMed:19909895 ]
  4. Authors unspecified: Clarithromycin. Tuberculosis (Edinb). 2008 Mar;88(2):92-5. doi: 10.1016/S1472-9792(08)70005-2. [PubMed:18486039 ]
  5. Champney WS, Burdine R: Macrolide antibiotics inhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureus. Antimicrob Agents Chemother. 1995 Sep;39(9):2141-4. [PubMed:8540733 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Keseru GM: Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5. [PubMed:12873512 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Fontana E, Dansette PM, Poli SM: Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab. 2005 Oct;6(5):413-54. [PubMed:16248836 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP: Structure-based identification of OATP1B1/3 inhibitors. Mol Pharmacol. 2013 Jun;83(6):1257-67. doi: 10.1124/mol.112.084152. Epub 2013 Apr 9. [PubMed:23571415 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP: Structure-based identification of OATP1B1/3 inhibitors. Mol Pharmacol. 2013 Jun;83(6):1257-67. doi: 10.1124/mol.112.084152. Epub 2013 Apr 9. [PubMed:23571415 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zuckerman JM, Qamar F, Bono BR: Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am. 2009 Dec;23(4):997-1026, ix-x. doi: 10.1016/j.idc.2009.06.013. [PubMed:19909895 ]
  2. Authors unspecified: Clarithromycin. Tuberculosis (Edinb). 2008 Mar;88(2):92-5. doi: 10.1016/S1472-9792(08)70005-2. [PubMed:18486039 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91. [PubMed:12124305 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  3. Egashira K, Ohtani H, Itoh S, Koyabu N, Tsujimoto M, Murakami H, Sawada Y: Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein. Drug Metab Dispos. 2004 Aug;32(8):828-33. [PubMed:15258108 ]
  4. Authors unspecified: Clarithromycin. Tuberculosis (Edinb). 2008 Mar;88(2):92-5. doi: 10.1016/S1472-9792(08)70005-2. [PubMed:18486039 ]
  5. Dey S, Gunda S, Mitra AK: Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption. J Pharmacol Exp Ther. 2004 Oct;311(1):246-55. Epub 2004 Jun 2. [PubMed:15175422 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T: Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22. Epub 2005 Feb 11. [PubMed:15708966 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 29, 2016 02:27